6533b7d0fe1ef96bd125ae71
RESEARCH PRODUCT
The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective.
Vincenzo PatellaIoana AgacheWienczyslawa CzarlewskiLudger KlimekTorsten ZuberbierKarl Christian BergmannNikolaos G. PapadopoulosClaus BachertErkka ValovirtaDésirée Larenas-linnemannAlvaro A. CruzMarek JutelJean BousquetJoão FonsecaOliver PfaarAziz SheikhM. T. VenturaNicola ScichiloneMohamed H. ShamjiFrederico S. RegateiroVioleta Kvedarienesubject
AllergyAllergen immunotherapymedicine.medical_specialtybusiness.industryHealth technologymedicine.diseaseRhinitis AllergicAsthmaTelemedicinelaw.inventionClinical trialRandomized controlled triallawDesensitization ImmunologicmedicineImmunology and AllergyHumansIntensive care medicinebusinessmHealthPatient stratificationAsthmadescription
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-12-09 | The journal of allergy and clinical immunology. In practice |